Research compound, not FDA-approved
The BPC-157 evidence base, graded claim by claim
Thirty-three years of animal and lab research, three small human pilot studies, zero published randomized human trials. Every claim on this site names the species it was tested in, carries an evidence-grade chip, and links to its study.
- 23primary studies in our graded evidence table
- 22of those are animal or laboratory studies
- 0published randomized human trials (the first is recruiting now)
- 44fetch-verified primary citations, 100% peer-reviewed, government, registry, or anti-doping authority
Online care, from intake to delivery
BPC-157 care, made simple
Choose your plan, complete a private medical intake, and connect with a licensed provider. If prescribed, treatment ships discreetly to your door.

Your care plan includes
Everything you need to get started
Encrypted checkout • provider review required • shipping included
- 01Choose your planSelect the supply and refill preference that works for you.
- 02Complete your intakeShare your health history in our private, secure flow.
- 03Provider reviewIf appropriate, your prescription is prepared and shipped.
Prescription treatment requires an online medical evaluation. A provider will determine whether treatment is medically appropriate; approval is not guaranteed.
Key facts
- StatusResearch compound, not FDA-approved
- Human PK studiesNone adequately characterized
- IM bioavailability14-19% rat; 45-51% dog
- Metabolism and excretionPeptide fragments to amino acids; urine and bile (animal radiolabel)
- PK-PD disconnectMinutes-long half-life vs effects reported for hours to days; unexplained
- Gastric-juice stabilityReported stable (chemical characterization; not an absorption claim)
- Oral bioavailability in humansNever measured
- ClassSynthetic pentadecapeptide (15 amino acids)
- SequenceGEPPPGKPADDAGLV
- Molecular weight1419.5 Da (C62H98N16O22)
- OriginFragment of gastric juice protein BPC; first characterized 1993
- July 2026 PCACFDA proposed BPC-157 NOT be added to the 503A compounding list
- WADA 2026Named under S0; prohibited at all times, in and out of competition
- Plasma half-lifeUnder 30 minutes (rats and dogs; echoed in a 2-subject human IV pilot)
- Human PKNo adequately characterized human PK study published
- Published human evidence3 uncontrolled pilot studies, under 30 subjects total
- Randomized human trials published0 (first phase 2 RCT recruiting since 2026)
- Animal evidenceRodent and rabbit models across tendon, muscle, bone, gut, nerve, cornea, vessels
- Established human doseNone. No published human dose-finding study exists
Browse by topic
Everything on BPC-157, organized the way you research it.
Free BPC-157 tools
Practical calculators and references, each scoped and sourced.
study rows by species, from the evidence table


All guides
131 in-depth, individually cited guides.
Evidence 32 guides
Comparisons 30 guides
Legal Status 29 guides
Sourcing 29 guides
Dosing 7 guides
Safety 4 guides


Follow the evidence, not the hype
One short email when this evidence base actually changes: new trial results, FDA rulemaking, and major safety updates.
